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Abstract
Persistent infection of basal keratinocytes with high-risk human papillomavirus (hrHPV) may cause cancer. Keratinocytes are
equipped with different pattern recognition receptors (PRRs) but hrHPV has developed ways to dampen their signals resulting in
minimal inflammation and evasion of host immunity for sustained periods of time. To understand the mechanisms underlying
hrHPV’s capacity to evade immunity, we studied PRR signaling in non, newly, and persistently hrHPV-infected keratinocytes. We
found that active infection with hrHPV hampered the relay of signals downstream of the PRRs to the nucleus, thereby affecting
the production of type-I interferon and pro-inflammatory cytokines and chemokines. This suppression was shown to depend on
hrHPV-induced expression of the cellular protein ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) in keratinocytes. UCHL1
accomplished this by inhibiting tumor necrosis factor receptor-associated factor 3 (TRAF3) K63 poly-ubiquitination which lead to
lower levels of TRAF3 bound to TANK-binding kinase 1 and a reduced phosphorylation of interferon regulatory factor 3.
Furthermore, UCHL1 mediated the degradation of the NF-kappa-B essential modulator with as result the suppression of p65
phosphorylation and canonical NF-kB signaling. We conclude that hrHPV exploits the cellular protein UCHL1 to evade host innate
immunity by suppressing PRR-induced keratinocyte-mediated production of interferons, cytokines and chemokines, which
normally results in the attraction and activation of an adaptive immune response. This identifies UCHL1 as a negative regulator of
PRR-induced immune responses and consequently its virus-increased expression as a strategy for hrHPV to persist.
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Introduction
Human papillomaviruses (HPVs) are absolutely species-specific
small double-stranded DNA viruses. Persistent infections with a
number of HPVs, predominantly types 16 and 18, can induce cancers
of the anogenitalia as well as of the head and neck region. These so-
called high-risk HPVs (hrHPVs) are widespread within all human
populations where they are commonly transmitted by sexual contact
[1]. The undifferentiated keratinocytes of the squamous epithelia are
the primary target for hrHPV [2] where it establishes an infection that
can last for up to 2 years, indicating that hrHPV has evolved
mechanisms to effectively evade the innate and adaptive immune
mechanisms protecting themajority of immunocompetent hosts [3,4].
Viruses and microbes contain pathogen-associated molecular
patterns that are recognized by the host’s pattern recognition
receptors (PRRs), comprising the Toll-like receptors (TLRs),
nucleotide oligomerization domain-like receptors and retinoic
acid-inducible gene I (RIG-I)-like receptors (RLRs) [5]. While all
of these receptors activate signaling cascades that lead to activation
of NF-kB via the canonical route, only RLRs and some TLRs
activate interferon regulatory factors (IRFs) which induce the
production of type I interferons (IFN) and other effector molecules
[6]. The signals from the PRR to the cell nucleus are coordinated
via ubiquitination, including that of the different tumor-necrosis
factor receptor-associated factors (TRAFs) and the NF-kB
essential modulator (NEMO). Poly-ubiquitination of TRAF and
NEMO allows downstream signaling whereas disassembly of
the formed poly-ubiquitin chains by deubiquitinating enzymes
provides a mechanism for downregulating immune responses
[6,7].
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Keratinocytes (KCs) express TLRs 1–3, TLR5, TLR6, TLR10,
RIG-I, protein kinase R (PKR), and MDA5 independent of their
differentiation status and gain the expression of TLR9 upon full
differentiation indicating that these cells may respond to pathogenic
challenges [8,9,10]. Thus, KCs should be able to sense the presence
of hrHPV genomic DNA directly via TLR9 or indirectly via RIG-I
[5,11,12]. The expression levels of these PRR were not altered in
hrHPV+KCs [10]. However, via genome-wide expression profiling
of keratinocytes activated through TLR3, PKR, RIG-I and MDA-5
we found that the presence of hrHPV dampens a network of genes
encoding chemotactic, pro-inflammatory and antimicrobial cyto-
kines suggesting that HPV’s immune evasion strategy may rely on
countering PRR-mediated cell signaling [10].
To understand the mechanisms underlying hrHPV’s capacity to
dampen PRR signaling we utilized a system that resembles the
natural infection with HPV as closely as possible. It comprises the use
of primary KCs that stably maintain the hrHPV genome as episomes
following transfection. These hrHPV+ KCs grow at similar rates as
non-transfected KC and have been shown to mimic HPV infection
in vivo as they undergo the entire differentiation-dependent HPV life
cycle documented by genome amplification, late gene expression,
and virus production, upon culture of hrHPV+ KCs in organotypic
raft cultures [13,14,15]. In addition, we used non-infected primary
KC cultures and primary KCs newly infected with authentic HPV16
virions. These primary KCs were compared with respect to PRR
signaling under different conditions and resulted in the identification
of the cellular enzyme ubiquitin carboxyl-terminal hydrolase L1
(UCHL1) that was specifically upregulated by hrHPV in primary
keratinocytes to dampen innate immunity. UCHL1 acted on the
PRR-signaling pathway adaptor molecules TRAF3 and NEMO and
its inhibition restored PRR-induced production of IFNb and pro-
inflammatory and chemotactic cytokines.
Results
High risk HPV is associated with a decreased induction of
type I IFN and pro-inflammatory cytokines following
stimulation of keratinocytes via different pattern-
recognition receptors
Undifferentiated uninfected primary KCs and hrHPV+ KCs
were tested for their capacity to respond to triggers of innate
immunity by incubation with Pam3CSK4 (TLR1/2), poly(I:C)
(TLR3, RIG-I, PKR and MDA-5) [9], lipopolysaccharide (LPS,
TLR4), flagellin (TLR5), R848 (TLR7/8), or CpG (TLR9). The
supernatant of non-infected keratinocytes contained higher levels
of MIP3a and IL-8 but not MIP1a than hrHPV+ KCs at the basal
level. Activation with poly(I:C) induced the production of high
amounts of MIP3a, IL-8 and MIP1a in KCs but not in hrHPV+
KCs. Flagellin especially triggered the production of MIP3a by
KCs but not in hrHPV+ KCs, although IL-8 was still produced
(Figure 1A). The function of TLR9, expressed only at high protein
levels in differentiated keratinocytes as measured by immunohis-
tochemistry [10] and by RT-qPCR (Figure 1B), was tested by the
capacity of CpG oligodeoxynucleotides (CpG ODN) to trigger the
expression of mRNAs of pro-inflammatory cytokines and
chemokines. Because suspension in methyl cellulose – to differen-
tiate keratinocytes – does not allow the harvest of supernatant,
secreted protein levels could not be measured. However, the
experiments clearly showed that CpG ODN-stimulation resulted
in the gene expression of IFNB1 (IFNb), IL-8 and CCL20 (MIP3a)
in differentiated KCs but not in undifferentiated KC cultures
(Figure 1C). As a control, KCs were also stimulated with poly(I:C)
as TLR3, RIG-I and MDA-5 expression is independent of KC
differentiation [10] and this resulted in the induction of pro-
inflammatory cytokine expression in both undifferentiated and
differentiated KCs (Figure S1). In contrast to differentiated
uninfected KCs, the hrHPV+ KCs that expressed TLR9 after
differentiation, failed to induce the expression of IFNb, IL-8 and
MIP3a upon incubation with CpG (Figure 1C), indicating that
PRR-signaling can be suppressed in undifferentiated and differ-
entiated hrHPV+ KCs.
As the basal KCs are the target for hrHPV and TLR9 is not
functionally expressed in basal KCs and hrHPV+ KCs displayed
an impaired production of cytokines in response to poly(I:C),
subsequent studies were performed in the context of poly(I:C)
stimulation. In addition to the secretion of cytokines, also the gene
expression levels of MIP3a, CCL5 (RANTES) and IFNb in hrHPV+
KCs were lower when compared to uninfected KCs upon 3 or
24 hours of poly(I:C) stimulation (Figure 2A).
The production of pro-inflammatory cytokines and chemokines
upon activation of the NF-kB pathway requires the phosphory-
lation and nuclear translocation of the subunit p65 [6]. The levels
of phosphorylated p65 were lower in poly(I:C) stimulated hrHPV+
KCs than in non-infected KCs (Figure 2B), suggesting that the
functional impairment of PRR signaling occurs upstream of this
molecule. The IKK complex is a key component of the poly(I:C)-
induced NF-kB pathway, with NEMO (IKKc) functioning as a
scaffold. The degradation of NEMO may form a mechanism for
viruses to avoid innate immune signaling [16,17]. Therefore, the
effect of hrHPV on the protein levels of NEMO was analyzed.
Following treatment of non-infected KCs and hrHPV+ KCs with
cycloheximide (CHX) – to prevent new protein synthesis – it
became clear that NEMO degradation was enhanced in hrHPV+
KCs (Figure 2C and Figure S2), thereby explaining the decreased
phosphorylation of p65 observed.
The production of type I IFN (e.g. IFNb) requires the activation
of cytosolic IRF3 by phosphorylation and subsequent translocation
to the nucleus. Analysis of poly(I:C) stimulated KCs and hrHPV+
KCs suggested that also the levels of phosphorylated IFR3 levels
were decreased in HPV+ KCs (Figure 2D).
The high risk HPV viral transcript is needed to impair PRR
signaling
To confirm that the impairment in the production of IFNb and
pro-inflammatory cytokines did not simply reflect biological
differences between the different primary KCs used but indeed
Author Summary
A persistent infection with high-risk human papillomavirus
(hrHPV) may cause cancer. Whereas keratinocytes – the cells
infected by hrHPV – are equipped with different receptors
allowing them to recognize invading pathogens and to
activate the immune system, hrHPV has developed ways to
evade the host’s immune response for sustained periods of
time. We showed that hrHPV accomplishes this by interfer-
ing with the signaling of the pathogen receptors, thereby
hampering the production of cytokines that are known to
attract and activate the immune system. HrHPV accomplish-
es this by upregulating the expression of a cellular protein
called ubiquitin carboxyl-terminal hydrolase L1 (UCHL1). This
protein suppresses the activation of signals downstream of
the pathogen receptor leading to reduced transcription
factor activation and downstream gene expression, in
particular that of type I interferon and pro-inflammatory
cytokines. This lowers the attraction of immune cells and
thereby the chance of hrHPV-infected cells to be recognized
and eliminated and as such enables hrHPV to persist.
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was caused by hrHPV, we infected primary keratinocytes with
infectious HPV16 virions (Figure 3A) for 24 hours and then
stimulated the non-infected and newly infected KCs with poly(I:C)
for another 24 hours after which the levels of IFNb, RANTES and
MIP3a transcripts were measured (Figure 3B). After 24 hours of
infection there was a small but discernible increase in the levels of
these genes indicating that the keratinocytes initially react to the
presence of the virus. However, the levels already dropped at
48 hours post-infection indicating that the virus rapidly exerted its
PRR-signaling inhibitory effects. In addition, at the same time
Figure 1. The presence of high risk human papillomavirus interferes with pattern recognition receptor (PRR) signaling of
keratinocytes. (A) Cytokine production of non-differentiated uninfected or HPV16+ keratinocytes after stimulation with different indicated PRR
stimuli as measured by ELISA. (B) TLR9 expression as measured by qRT-PCR on total RNA samples from undifferentiated (und) and terminally
differentiated (terminal dif) uninfected KCs, and HPV16 and HPV18 positive KC cultures. (C) IFNb, IL-8 and MIP3a expression levels in unstimulated or
CpG ODN-stimulated uninfected KCs, and two different HPV (16 or 18) positive KC cultures as examined by qRT-PCR. KCs were either left
undifferentiated (und) or terminally differentiated (terminal dif) after which they were stimulated with CpG (10 mg/ml) for 7 hours. (B–C) Gene
expression was normalized using GAPDH mRNA expression levels.
doi:10.1371/journal.ppat.1003384.g001
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point these newly hrHPV-infected keratinocytes displayed a
hampered activation of IFNb, RANTES and MIP3a following
24 hours of stimulation with poly(I:C) (Figure 3B). Moreover, we
repressed the polycistronic viral mRNA transcript [18,19] in
hrHPV+ KCs by the use of siRNA targeting HPV16 E2 as this
allows the destruction of the whole RNA chain. Indeed the
suppression of HPV early gene E2 expression translated into an
overall decrease in viral early gene expression (Figure 3C) and an
increase in the transcription of IFNb, RANTES and MIP3a
following poly(I:C) stimulation (Figure 3D).
Together these data demonstrate that the innate immune
response to viral and bacterial-derived PRR stimuli of both
undifferentiated and differentiated hrHPV+ keratinocytes is
suppressed by HPV at a point downstream of the PRR receptors
but upstream of the transcription factors that relay the PRR
signals to the nucleus.
The ubiquitin-modifying enzyme UCHL1 is over-
expressed in hrHPV-positive keratinocytes and
responsible for suppressing the production of type I IFN
as well as pro-inflammatory and chemotactic cytokines
Our data suggest that hrHPV+ keratinocytes manifest a
generalized inability to respond to stimulation through interfer-
ence at, or downstream of the cytosolic part of the PRR signaling
pathways. We therefore re-analyzed the genome-wide expression
profiles (Gene Expression Omnibus accession number GSE21260)
of several different uninfected KC cultures and hrHPV+ KC
cultures reported previously [10] by Ingenuity Pathways Analysis
(IPA) and found a highly significant enrichment of genes belonging
to the protein ubiquitination pathway (Table S1; p = 6.6961025).
In this pathway, the gene for the enzyme ubiquitin carboxyl-
terminal hydrolase L1 (UCHL1) was the most upregulated gene in
Figure 2. Canonical NF-kB signaling is impaired upstream of the transcription factor p65. (A) Poly(I:C) induced cytokine expression in
HPV16+ KCs compared to non-infected KCs. MIP3a, RANTES and IFNb expression was measured by qRT-PCR. Gene expression was normalized using
GAPDH mRNA levels and standardized against 0 h of stimulation with poly(I:C). (B) Poly(I:C) stimulated phosphorylation levels of p65 in HPV16+ KCs
compared to non-infected KCs. Total p65 levels and p65 phosphorylation status were determined in whole cell extracts by western blotting. b-actin
served as loading control. (C) NEMO degradation in HPV16+ KCs compared to non-infected KCs. Monolayer cultures were treated with 100 mM
cycloheximide (CHX) and harvested after 0, 3, 6, 9, 12, 18 and 24 hours. Whole cell extracts were analyzed by western blotting using antibodies
against NEMO and b-actin (control for protein degradation). (D) Poly(I:C) stimulation-induced phosphorylation levels of IRF3 in hrHPV+ KCs compared
to KCs. Total IRF3 levels and IRF3 phosphorylation status were determined in whole cell extracts by western blotting. b-actin served as loading
control.
doi:10.1371/journal.ppat.1003384.g002
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hrHPV+ KCs compared to uninfected KCs (Figure 4A and B).
The upregulation of UCHL1 in hrHPV+ KCs was confirmed by
RT-qPCR in both foreskin and vaginal epithelial hrHPV+ KC
cultures and expression was not influenced by poly(I:C) activation
(Figure 4C). Furthermore, UCHL1 upregulation at the protein
level was tested and shown for three different hrHPV+ KCs by
Figure 3. Expression of human papillomaviral transcripts are required to impair cytokine expression of poly(I:C) stimulated
keratinocytes. (A, B) Cytokine expression at the initial stage of HPV16 infection. Primary basal layer human foreskin keratinocytes were infected
with native HPV16. (A) Viral early gene E6 expression was analyzed 1 and 2 (24 h poly(I:C)) days after infection by PCR. NC: negative control, PC:
positive control, HPV16+ KCs. (B) MIP3a, RANTES and IFNb expression was measured by qRT-PCR. Gene expression was normalized against GAPDH
mRNA levels and standardized against the 0 h poly(I:C) stimulated non-infected cells. Similar results were observed in two independent experiments.
(C, D) Poly(I:C)-induced cytokine expression in HPV+ KCs transfected with control siRNA (siControl) or siRNA targeting HPV16 E2 (siHPV16 E2). E1, E2,
E6, E7 (C) as well as MIP3a, RANTES, and IFNb (D) expression was analyzed by qRT-PCR. Gene expression was normalized against GAPDH mRNA levels
and standardized against no poly(I:C) siControl. For all three genes the response to poly(I:C) was significantly higher when HPV16 E2 was suppressed
(p,0.001, one-way ANOVA).
doi:10.1371/journal.ppat.1003384.g003
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Figure 4. HPV induces expression of UCHL1 in keratinocytes. (A) Summary of all differentially expressed genes within the Protein
Ubiquitination Pathway. Differentially expressed genes between four uninfected KC and four hrHPV+ KC cultures with adjusted p-value#0.05
identified 24 hours after poly(I:C) stimulation by microarray analysis (log2 ratios) are shown. (B) UCHL1 microarray gene expression values (log2
intensities) after 0, 4, and 24 hours of poly(I:C) stimulation in four primary KCs and four hrHPV+ KCs (circles). The box represents the 25th and 75th
percentiles, the median is indicated with a horizontal line within the box, and the whiskers represent the minimum and maximum. (C) UCHL1
expression in HPV16+ human foreskin keratinocytes (HFK; left panel) and HPV16+ human vaginal keratinocytes (HVK; right panel) when compared to
uninfected KCs. KCs were either left unstimulated or stimulated with poly(I:C) for 24 hrs. UCHL1 expression was normalized against GAPDH. (D) UCHL1
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western blotting (Figure 4D). Moreover, expression of UCHL1 was
upregulated 2 days post-infection of HPV16 in primary keratino-
cytes when compared to mock-infected primary keratinocytes
(Figure 4E), whereas knock-down of the polycistronic viral mRNA
transcript in hrHPV+ KCs by siRNA for HPV16 E2 resulted in a
decreased UCHL1 expression (Figure 4F). Thus, the cellular
deubiquitinase UCHL1 is upregulated by hrHPV.
Although UCHL1 had not been associated with the inhibition
of PRR signaling, its enhanced expression in hrHPV+ KCs fits
well with the general role of deubiquitinases in controlling PRR
signaling [6]. To test whether hrHPV-induced UCHL1 inhibits
PRR signaling, we used lentiviral vectors expressing short-hairpin
RNA (shRNA) against UCHL1 and this resulted in a downregu-
lated expression of UCHL1 transcripts and protein levels in
hrHPV+ KCs (Figure 5A and B). Upon stimulation with poly(I:C),
hrHPV+ KCs expressing shRNA against UCHL1 (shUCHL1) but
not hrHPV+ KCs expressing a control shRNA (shControl)
restored poly(I:C)-mediated induction of type I interferon and
proinflammatory cytokines (Figure 5C). Similar results were
obtained using transiently transfected RNA interference (RNAi)
oligos targeting UCHL1 but not with control RNAi oligos (Figure
S3). An increase in the expression levels of IL8 and MIP3a was
detected in hrHPV+ KCs in which UCHL1 was downregulated.
Gene expression increased to the same levels found in UCHL1-non
silenced hrHPV+ KCs cells stimulated with poly(I:C) (Figure S3).
This suggests that downregulation of UCHL1 increases the gene
expression of IL-8 and MIP3a in hrHPV+ KCs. Conversely,
transfection of uninfected KCs to overexpress UCHL1 resulted in a
decreased expression ofMIP3a, RANTES and IFNb upon poly(I:C)
stimulation (Figure 5D and E). Based on control experiments in
which KCs were transfected with green fluorescent protein
expressing plasmids, the transfection efficiency of keratinocytes
was 30–40% (not shown), indicating that in a large part of the
keratinocytes the activation of cytokine-encoding genes is not
impaired and explaining the expression levels of these cytokine-
encoding genes that are still detected.
All together, these data clearly demonstrate that UCHL1 can
downregulate the PRR-mediated activation of both the type I IFN
and proinflammatory cytokine and chemokine pathways.
Knock down of UCHL1 increases the phosphorylation of
IRF3 and NFkB p65 and alleviates NEMO degradation
We then asked whether the restoration of PRR signaling, as
indicated by an increased induction of type I interferon and
proinflammatory cytokines by the knock down of UCHL1 in
hrHPV+ KCs would also be reflected in the levels of phosphor-
ylated p65 (p65-p) and IRF3 (IRF3-p) upon poly(I:C) stimulation.
Therefore, the p65-p and IRF3-p levels were analyzed in whole
cell extracts of HPV16+ KCs stably expressing shRNA against
UCHL1 or control shRNA and following 3 h or 24 h of
stimulation with poly(I:C). Knock down of UCHL1 in hrHPV+
KCs resulted in increased p65 phosphorylation at 3 and 24 hours
after poly(I:C) stimulation (Figure 6A) coinciding with enhanced
cyto- and chemokine production (Figure 5C). In addition, analysis
of hrHPV+ KCs treated with cycloheximide revealed that NEMO
degradation was alleviated when UCHL1 was knocked down by
shUCHL1 as compared to the shControl hrHPV+ KCs
(Figure 6B). Furthermore, higher levels of phosphorylated IRF3
were detected in hrHPV+ KCs in which UCHL1 was knocked
down as compared to hrHPV+ KCs expressing the shControl after
3 hours of poly(I:C) stimulation (Figure 6C).
UCHL1 alters the poly-ubiquitination of TRAF3 and NEMO
TRAF3 ubiquitination is critical for type I IFN production and
is a likely target for ubiquitin-modifying enzymes such as UCHL1.
As the biochemical experiments to understand the nature of this
interaction would require substantial amounts of primary KCs,
which can only grow for a few passages thereby restricting their
use in biochemical studies, we switched to the HEK293T cell
system that is widely used for these purposes. To investigate the
interaction between UCHL1 and TRAF3 we overexpressed
UCHL1 and Flag-tagged TRAF3 in HEK293T cells. After FLAG
immunoprecipitation, we confirmed that UCHL1 co-immunopre-
cipitated with TRAF3 (Figure 7A). TRAFs are activated by
oligomerization and auto-ubiquitination, a process that results in
lysine 63 (K63)-linked poly-ubiquination of TRAF, and this event
can be induced by either their overexpression or by receptor
activation. In contrast K48-linked poly-ubiquitination results in
proteasome-mediated degradation of ubiquitinated TRAFs [6].
To test whether UCHL1 modified TRAF3 ubiquitination status,
Flag-tagged TRAF3 and haemagglutinin A (HA)-tagged ubiquitin
were overexpressed in control or UCHL1 overexpressing
HEK293T cells. Poly-ubiquitination of TRAF3 was clearly visible
by immunoblot analysis but strongly reduced when UCHL1 was
also overexpressed (Figure 7B, Figure S4). No reduction in poly-
ubiquitination was detected when as a control the growth
regulated ubiquitin-specific protease 8 (USP8), which similar to
UCHL1 displays carboxyl-terminal hydrolase activity, was over-
expressed (Figure 7B). The UCHL1-associated decreased detec-
tion of poly-ubiquitinated TRAF3 was not the result of increased
TRAF3 degradation as blocking the proteasomal degradation
pathway by the inhibitor MG132 did not result in a reappearance
of poly-ubiquitinated TRAF3 (Figure 7C). Instead, experiments in
which HA-tagged ubiquitin mutants ‘K63 Only’ and ‘K48 Only’
(where all lysine residues, except at position K63 and K48,
respectively, were mutated to arginine) showed that UCHL1
removed K63-linked poly-ubiquitins but not K48-linked poly-
ubiquitins (Figure 7D), consistent with the known deubiquitinating
capacity of UCHL1 [20]. K63-linked ubiquitination is required for
TRAF3 to bind its partner TBK1 to activate the downstream type
I IFN-signaling pathway. As expected, UCHL1-mediated deubi-
quitination of TRAF3 resulted in less TRAF3 bound to TBK1 in
UCHL1 overexpressing cells when compared to control cells
(Figure 7E). These data clearly show that UCHL1 binds and
deubiquitinates TRAF3 resulting in a decreased TRAF3-TBK1
complex formation.
Poly-ubiquitination of TRAF6 and its downstream partner
NEMO is critical for the PRR-induced activation of proinflam-
matory cytokine genes [6]. Since the overexpression of UCHL1
protein levels in HPV16+ human foreskin keratinocytes (HPV16) and HPV16+ or HPV18+ human vaginal keratinocytes (HVK16 or HVK18, respectively)
when compared to non-infected KCs (HFK) as detected by western blotting (WB) in whole cell extracts. b-actin served as loading control. (E) UCHL1
expression at the initial stage of HPV16 infection. Primary basal layer human foreskin keratinocytes were infected with native HPV16 (HPV16 infected
keratinocytes) or not (Mock). UCHL1 mRNA expression was analyzed by qRT-PCR 2 days after infection. Gene expression was normalized against
GAPDH mRNA levels and standardized against the non-infected cells. Similar results were observed in two independent experiments. (F) UCHL1
expression in HPV+ KCs transfected with control siRNA (siControl) or siRNA targeting HPV16 E2 (siHPV16 E2). UCHL1 expression was analyzed by qRT-
PCR. Gene expression was normalized against GAPDH mRNA levels and standardized against siControl. Similar results were observed in more than 3
independent experiments.
doi:10.1371/journal.ppat.1003384.g004
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Figure 5. UCHL1 is responsible for suppressing poly(I:C) mediated gene activation of IFN-I and proinflammatory cytokines in
hrHPV-infected KC. (A–C) UCHL1 knock-down effect of poly(I:C) mediated gene expression of IFN-I and proinflammatory cytokines. HPV16+
keratinocytes were transduced with lentiviral vectors expressing shRNA against control mRNA (TurboGFP; shControl) or targeting mRNA of UCHL1
(shUCHL1). Cells were either left unstimulated, or were stimulated with poly(I:C) for 3 or 24 hrs. (A) UCHL1mRNA expression was analyzed by qRT-PCR
and (B) UCHL1 protein levels were analyzed by western blotting in whole cell extracts, b-actin served as loading control. (C) MIP3a, RANTES and IFNb
mRNA expression was analyzed by qRT-PCR. Gene expression was normalized against GAPDH mRNA levels and standardized against 0 h of
stimulation with poly(I:C). (D, E) UCHL1 overexpression effect on the activation of poly(I:C) mediated gene expression of IFNb and proinflammatory
cytokines. Uninfected keratinocytes were transfected with a vector harboring the UCHL1 gene, an empty control or only received the transfection
agent (TFRO). Cells were either left unstimulated, or were stimulated with poly(I:C) for 24 hrs. (D) UCHL1 protein levels were upregulated in the
UCHL1-transfected cells as detected by western blotting in whole cell extracts, b-actin served as loading control. (E) MIP3a and RANTES mRNA
expression was analyzed by qRT-PCR. Gene expression was normalized against GAPDH mRNA levels and standardized against the TFRO at 0 h of
stimulation with poly(I:C).
doi:10.1371/journal.ppat.1003384.g005
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clearly affected proinflammatory cytokine synthesis (Figure 5) the
interaction of UCHL1 with TRAF6 and NEMO was tested. Co-
expression and immunoprecipitation experiments in HEK293T
cells showed that UCHL1 bound to TRAF6 but not to NEMO
(Figure 7A). In contrast to what we observed for TRAF3, UCHL1
displayed a modest effect on the poly-ubiquitination of TRAF6
Figure 6. UCHL1 reduces phosphorylation levels of IRF3 and p65 and degrades NEMO in hrHPV-positive KC. (A) UCHL1 knock down
effect on poly(I:C) stimulated p65 phosphorylation in HPV16+ keratinocytes. Monolayer cultures of shControl or shUCHL1-expressing HPV16+ KCs
were stimulated for 0, 3 or 24 hours with Poly(I:C). Whole cell extracts were analyzed by western blotting for p65, p65-p and b-Actin (as loading
control). The relative expression of p65-p was quantified by measuring its density and by normalizing it to that of b-Actin. The expression levels of
p65-p in the 0 h Poly(I:C) cells were set to 100% for both shControl and shUCHL1 cells. The p65-p levels in the 3 h and 24 h Poly(I:C) cells were
calculated against the levels measured at 0 h Poly(I:C) (right panel). (B) NEMO protein levels after knock down of UCHL1 in HPV16+ KCs. Monolayer
cultures of shControl or shUCHL1-expressing HPV16+ KCs were treated with 100 mM cycloheximide (CHX) for 16 hours. Whole cell extracts were
analyzed by western blot using antibodies against NEMO and b-Actin (control for protein content). The relative expression of NEMO was quantified
by measuring its density and by normalizing it to that of b-Actin. The expression of NEMO in the DMSO control was set to 100% (right panel). (C)
UCHL1 knock down effect on poly(I:C) stimulated IRF3 phosphorylation in HPV16+ keratinocytes. Similar to A, however cell extracts were analyzed by
western blotting using antibodies against IRF3, IRF3-p and b-Actin (as loading control). The relative expression of IRF3-p was quantified by measuring
its density and by normalizing it to that of b-Actin. The expression of IRF3-p in the 3 h Poly(I:C) control cells (no knock down of UCHL1) was set to
100% (right panel).
doi:10.1371/journal.ppat.1003384.g006
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(Figure 8A). However, poly-ubiquitination of NEMO was reduced
in UCHL1 overexpressing cells (Figure 8B, Figure S4) but not in
USP8 overexpressing cells (Figure 8D). Inhibition of proteasome
function by MG132 suggested that the reduced poly-ubiquitina-
tion of NEMO was the result of enhanced degradation of NEMO
in cells overexpressing UCHL1 (Figure 8C, compare lanes 2 and
4), albeit that the total protein levels of NEMO in these transfected
cells remained unaffected. This is not unexpected as also in the
endogenous setting (Figures 2 & 6) the degradation of NEMO
could only be visualized when the hrHPV+ KCs where pretreated
with cycloheximide to prevent new protein synthesis.
Collectively, these data support the notion that UCHL1 can
suppress the PRR-signaling pathways necessary for type I IFN and
pro-inflammatory cytokine production by the removal of the
activating K63 ubiquitins from TRAF3 and the forced degrada-
tion of NEMO.
Discussion
We have employed a unique model for hrHPV infection to
examine the potential mechanisms underlying the capacity of
hrHPV to evade host immunity by suppression of the innate
immune response [10]. We utilized primary KC cultures that were
newly infected with HPV16 virions or primary KCs stably
maintaining the episomal hrHPV genome to show that despite
the expression of multiple PRRs the production of IFNb and pro-
inflammatory cytokines and chemokines is suppressed by hrHPV
as a consequence of reduced PRR signaling. We provided firm
evidence that this suppression depends on the hrHPV-induced
upregulation of the cellular ubiquitin-modifying enzyme UCHL1
in infected primary KCs.
Finally, classical biochemical studies in HEK293T cells
[11,21,22] performed to understand how UCHL1 mechanistically
could suppress the production of type I interferons and pro-
inflammatory cytokines revealed that UCHL1 regulated the
ubiquitination of the PRR-signaling pathway adaptor molecules
TRAF3 and NEMO. UCHL1 removes activating K63-linked
ubiquitin molecules from TRAF3 resulting in a lower amount of
the downstream signaling complex TRAF3-TBK-1 to suppress the
type I IFN pathway. This puts UCHL1 within the family of other
deubiquinating enzymes that regulate the PRR pathways by
selectively cleaving lysine-63 (K63)-linked ubiquitin chains from
TRAFs (e.g. DUBA, OTUB1, OTUB2, A20) [21,22,23,24,25,26].
Furthermore, we showed that UCHL1 bound to TRAF6 and
mediated the enhanced degradation of NEMO as a mechanism to
suppress the proinflammatory cytokine NF-kB pathway. Notably,
the ubiquitin-modifying enzyme A20, a known negative regulator
of the TLR pathway, has two ubiquitin-editing domains allowing
it to remove and to add ubiquitin chains (22, 26). UCHL1 has also
been reported to have these two opposing functions (20). The
ligase activity of UCHL1 may explain the ubiquitination of
TRAF6 observed in our study. Although UCHL1 did not bind to
NEMO, it is known that other deubiquitinating enzymes (e.g.
CYLD, A20) bind to TRAFs in order to dock on the IKK complex
and to associate with NEMO [21,27]. TRAF6-dependent poly-
ubiquitination of NEMO is well known [28]. It is highly likely that
UCH-L1 acts in a similar fashion and this would fit with TRAF6-
NEMO interaction and our observations that NEMO is degraded.
Our data on the suppression of NF-kB signaling via the
degradation of NEMO by UCHL1 fits well with earlier
observations concerning the overexpression of UCHL1 in vascular
cells. Here UCHL1 attenuated TNF-a induced NF-kB signaling
and this was associated with stabilization of IkBa and a decrease in
its basal ubiquitination [29]. The activation of NF-kB signaling
requires IkBa to become degraded following an interaction with
the IkB kinase complex (IKK) which comprises NEMO. Hence,
the degradation of NEMO may explain previous observations on
UCHL1-associated stabilization of IkBa.
UCHL1 is not found to be central in the network of genes
affected by hrHPV, suggesting that it is not part of the cellular
genes affected in order to assist in HPV genome replication and
viral protein production [10]. This indicates that UCHL1 is not
directly involved in viral propagation but rather recruited by
hrHPV to suppress keratinocyte-mediated production of cytokines
and chemokines that would result in the attraction and activation
of an adaptive immune response, thereby enabling the virus to
persist and propagate.
Many viruses utilize multifunctional viral proteins in order to
evade NF-kB- and IRF-mediated immune responses, to favor viral
replication and/or to modulate cellular apoptosis and growth
pathways [30]. The group of pox viruses have evolved to inhibit
NF-kB-signaling by targeting one or more of the many different
molecules of this signaling cascade [31]. The vaccinia virus B14
protein is known to inhibit NF-kB signaling by a variety of toll-like
receptor agonists at the level of the IKK complex, of which
NEMO is a member [32]. The vaccinia virus A64R protein
inhibits TRIF-TRAF3-IRF signaling [33]. The pathogenic NY-1
hantavirus Gn protein inhibits TRAF3 signaling by blocking the
formation of TBK1-TRAF3 complexes [34] whereas the LMP1
protein of Epstein-Barr virus directly binds to TRAF3 [35].
Furthermore, foot-and-mouth disease virus 3c protease cleaves
NEMO [16] and cytomegalovirus M54 protein induces the
proteasome-independent degradation of NEMO [17]. In contrast,
human papillomaviruses, with a rather limited coding capacity in
their genomes, rely for many aspects of their life cycle on the
utilization of cellular proteins [36] and this includes the
recruitment of different cellular E3 ligases to mediate degradation
of cellular proteins through the ubiquitin-proteasomal pathway
[37]. UCHL1 is one of the most abundant proteins in the
mammalian nervous system and is involved in regulating synaptic
Figure 7. Interaction of UCHL1 with the PRR downstream signaling molecule TRAF3. (A) UCHL1 directly interacts with TRAF3 and TRAF6
but not NEMO. HEK293T cells were co-transfected as indicated and the respective TRAF3, TRAF6 or NEMO proteins were immunoprecipitated using
Flag antibody, and co-precipitating UCHL1 was detected by WB. As a control a WB analysis for Flag was performed indicating that both TRAF3 and
NEMO were present. The bottom three panels show a WB analysis of Flag and UCHL1 of non- immunoprecipitated lysate and a Ponceau S stained
loading control for WB. (B) UCHL1, but not the control ubiquitin-specific protease 8 (USP8) mediates deubiquitination of TRAF3. HEK293T cells were
co-transfected with Flag-TRAF3, HA-tagged wild-type ubiquitin (WT-Ub), and with either empty vector, WT UCHL1 or USP8. TRAF3 was
immunoprecipitated with Flag antibody and WB was done with HA or Flag antibodies (top panels). The bottom four panels show a WB analysis of
Flag, UCHL1, and USP8 of non- immunoprecipitated lysate and a Ponceau S stained loading control for WB. (C) Deubiquitination but not degradation
of TRAF3 by UCHL1. HEK293T cells were co-transfected with Flag-TRAF3, HA-tagged wild-type ubiquitin (WT-Ub), and with either empty vector or WT
UCHL1. Cells were left untreated or treated with proteasome blocker MG132. TRAF3 was immunoprecipitated with Flag antibody and WB was done
with HA or Flag antibodies (top two panels). (D) UCHL1 mainly removes K63-linked poly-ubiquitin chains of TRAF3. HEK293T cells expressing Flag-
TRAF3, HA-tagged mutant ubiquitin either K63 Only or K48 Only, and WT UCHL1 were immunoprecipitated with Flag antibody and analyzed by HA or
Flag antibodies (top two panels). (E) UCHL1 lowers TRAF3-TBK1 complex formation. HEK293T cells were co-transfected and TBK1 was
immunoprecipitated using Flag antibody, and co-precipitating TRAF3 or TBK1 was detected by WB (top two panels).
doi:10.1371/journal.ppat.1003384.g007
HPV Upregulates UCHL1 to Suppress Immune Responses
PLOS Pathogens | www.plospathogens.org 11 May 2013 | Volume 9 | Issue 5 | e1003384
Figure 8. Interaction of UCHL1 with the PRR downstream signaling molecules TRAF6 and NEMO. (A) UCHL1 overexpression results in a
modest poly-ubiquitination of TRAF6. HEK293T cells were co-transfected with Flag-TRAF6, HA-tagged WT-Ub, and with either empty vector or WT
UCHL1. TRAF6 was immunoprecipitated with Flag antibody and western Blotting (WB) was done with HA or Flag antibodies (top two panels). The
bottom three panels show a WB analysis of UCHL1 and Flag of non-immunoprecipitated lysate and a Ponceau S stained loading control for WB. (B)
The effect of UCHL1 on NEMO. HEK293T cells were co-transfected with Flag-NEMO, HA-tagged WT-Ub, and with either empty vector or WT UCHL1.
NEMO was immunoprecipitated with Flag antibody and WB was done with HA or Flag antibodies (top two panels). (C) The overexpression of UCHL1
mediates the degradation of NEMO. HEK293T cells were co-transfected with Flag-NEMO, HA-tagged WT-Ub, and with either empty vector or WT
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transmission at the neuromuscular junctions [38]. Aberrant
expression is related to Parkinson’s disease [20] and is also
implicated in oncogenesis [39]. In hrHPV+ keratinocytes UCHL1
is expressed and redirected to adopt a new function that is to serve
as a negative regulator of the PRR-signaling pathway. As such it
mimics the ubiquitin-modifying enzyme A20 which is the natural
negative regulator of the TLR pathway [22,26,40]. UCHL1
interferes with the adaptor molecules TRAF3, TRAF6 and
NEMO which all function at junctions for the immune stimulating
signals from different PRR and type I IFNR to activate NF-kB-
and IRF-mediated immune responses. Therefore, the utilization of
UCHL1 represents a truly effective use of a cellular protein as it
may suppress the immunostimulatory signals initiated through
recognition of HPV genomic DNA by TLR9 [5] and RIG-I
[11,12] as well as those obtained via the cell surface receptors for
type I IFN [41].
The high expression of UCHL1 in primary keratinocytes
carrying infectious hrHPV [13,14] is generally lost after transfor-
mation of these keratinocytes to tumor cells. Although transformed
keratinocytes expressing un-physiologically high levels of E6 and
E7 via retroviral transduction still may express UCHL1, only a
minority of spontaneously HPV-transformed cervical carcinoma’s
and none of the well known HPV-induced cancer cell lines
overexpress UCHL1 [42], indicating that under normal conditions
UCHL1 overexpression in HPV transformed cells is not a common
event. The expression of the hrHPV oncoproteins E6 and E7 is
required to maintain the transformed state of keratinocytes [2,43]
suggesting that it is not E6 or E7, but one or more of the other
viral proteins responsible for upregulation of UCHL1 (currently
under investigation). Previous studies on the innate immune
response to hrHPV relied on the overexpression of hrHPV E6
and/or E7 proteins, showing that the viral DNA-sensing TLR9
was altered [8] and that overexpressed HPV E6 or E7 could bind
to IRF3 [44] and/or the co-activator CPB [45]. Furthermore,
overexpressed hrHPV E6 and/or E7 attenuated IkB kinase
signaling [46], and interfered with the nuclear translocation of the
interferon-stimulated gene factor 3 (ISGF3) transcription complex
[47]. The fact that these studies were performed with only HPV
E6- and E7 transfected or transformed cells may explain why the
central role of UCHL1 in dampening immunity towards hrHPV+
keratinocytes was not discovered before. In addition, the loss of
UCHL1 mediated suppression of the NF-kB pathway in hrHPV
E6/E7-induced cancer cells fits well with the notion that solid
tumors require the NF-kB-mediated expression of proteins that
promote survival, proliferation, invasion and metastasis [48] which
is acquired through the E6-mediated deactivation of CYLD [49], a
negative regulator of TRAF2 and TRAF6-mediated activation of
NF-kB [21,24].
All together, our data implicate UCHL1 as a negative regulator
of the PRR pathways helping hrHPV to evade host immunity and
allowing it to persist in keratinocytes.
Methods
Cell culture
Primary cultures of human epithelial keratinocytes were
established from foreskin [50] and vaginal tissues and grown in
serum-free medium (Defined KSFM, Invitrogen, Breda, The
Netherlands). Keratinocyte lines stably maintaining the full
episomal HPV genome following electroporation were grown in
monolayer culture using E medium in the presence of mitomycin
C treated J2 3T3 feeder cells [13,14] for two passages and were
then adapted to Defined K-SFM for one passage before
experimentation. None of the cell cultures were used after passage
15 and the non-transformed state of the cells used was confirmed
by the expression of both E1 and E2 so that the cells used truly
represent the preneoplastic state in which the HPV genomes
remained episomal and were capable of the complete viral life
cycle. Keratinocytes were terminally differentiated by placing
them into serum-free medium containing 1.75% methyl cellulose
and 1.8 mM Ca2+ for 24 hours [50]. Cells were harvested by
washing out the methyl cellulose three times. HEK293T cells were
cultured in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum, 2 mM l-glutamine and 1%
penicillin-streptomycin (Gibco-BRL, Invitrogen). Transient trans-
fections were performed using calcium phosphate or Lipofecta-
mine 2000 (Invitrogen).
HPV16 infection of non-infected keratinocytes
Primary basal layer human foreskin keratinocytes were seeded
at 7.56104 cells per well of a 24-wells plate in K-SFM and then
allowed to attach for 48 hours. Cells received fresh medium (Mock
infected) or medium containing native HPV16 isolated from raft
cultures at a MOI 100 for 24 hours. Cells were stimulated with or
without 25 ug/ml poly(I:C) in K-SFM for 0 or 24 hours and
harvested at the indicated time-points.
Plasmid construction
Full length human cDNA clones for UCHL1, TRAF3, TRAF6
and TBK1 were obtained from Open Biosystems (Surrey, UK).
The cDNA clones were PCR amplified and subcloned either into
pcDNA3.1 expression vector or into Flag-tagged pcDNA3.1
vector. Full-length Flag-NEMO construct was kindly provided
by Dr. C. Sasakawa, University of Tokyo, Japan [51]. HA-tagged
wild-type and mutant ubiquitin constructs were kindly provided by
Dr. A. Iavarone, Columbia University, USA.
RNA expression analyses
Total RNA was isolated using TRIzol (Invitrogen) according to
manufacturer’s instructions. RNA was purified using RNeasy Mini
Protocol (Qiagen, Venlo, The Netherlands). Total RNA (0.2 mg)
was reverse transcribed using SuperScript III reverse transcriptase
(Invitrogen) and oligo dT primers (Promega, Madison, USA).
TaqMan PCR was performed using TaqMan Universal PCR
Master Mix and pre-designed, pre-optimized primers and probe
mix for IL-8, MIP-1a, MIP-3a, RANTES, IL-1b, IFNb, UCHL1
and GAPDH (Applied Biosystems, Foster City, USA). Threshold
cycle numbers (Ct) were determined using the 7900HT Fast Real-
Time PCR System (Applied Biosystems) and the relative quantities
of mRNA per sample were calculated using the DDCt method as
described by the manufacturer using GAPDH as the calibrator
gene.
Stimulation of cells with TLR ligands and ELISA
56105 cells were plated in 1 ml in each well of 24-well flat
bottom plate. Cells were left unstimulated or stimulated with
UCHL1. Cells were left untreated or were treated with MG132, NEMO was immunoprecipitated with Flag antibody and WB was done with HA or Flag
antibodies (top two panels). (D) USP8 does not deubiquitinate NEMO. HEK293T cells were co-transfected with Flag-NEMO, HA-tagged wild-type
ubiquitin (WT-Ub) and UCHL1 or USP8. NEMO was immunoprecipitated with Flag antibody and WB was done with HA antibodies (top panel). The
bottom four panels show a WB analysis of Flag, UCHL1, and USP8 of non-immunoprecipitated lysate and a Ponceau S stained loading control for WB.
doi:10.1371/journal.ppat.1003384.g008
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Pam3CSK4 (5 mg/ml), Poly(I:C) (25 mg/ml), LPS (3.33 mg/ml ),
flagellin (150 ng/ml), R848 (1 mg/ml), CpG (1 mM) or TNFa
(50 ng/ml) for 24 hours. Flagellin was a kind gift from Jean-
Claude Sirard (Institut Pasteur, Lille, France). TLR ligands were
purchased from Invivogen (San Diego, USA). The supernatants
were harvested and IL-8, MIP-3a, and MIP-1a concentrations
were determined using corresponding Quantikine ELISA kits
(R&D Systems, Oxon, UK).
RNAi and shRNA
Non-targeting RNAi oligos (ON-TARGETplus Non-targeting
Pool, catalogue D-001810-10-20) and oligos targeting UCHL1
(ON-TARGETplus SMARTpool, catalogue L-004309-00) were
purchased from Dharmacon (Chicago, IL). Cells were transfected
with RNAi using N-TER Nanoparticle siRNA Transfection
System (Sigma-Aldrich, St. Louis, MO) according to manufactur-
er’s instructions. 24 hours after transfection, cells were stimulated
with poly(I:C) (25 mg/ml) for another 24 hours and experiments
were performed.
The shRNA’s used were obtained from the MISSION TRC-
library of Sigma-Aldrich (Zwijndrecht, The Netherlands). The
MISSION shRNA clones are sequence-verified shRNA lentiviral
plasmids (pLKO.1-puro) provided as frozen bacterial glycerol
stocks (Luria Broth, carbenicillin at 100 mg/ml and 10% glycerol)
in Escherichia coli for propagation and downstream purification of
the shRNA clones. pLKO.1 contains the puromycin selection
marker for transient or stable transfection. The construct against
UCHL1 (NM_004181) was TRCN0000011079 (LV079): CCG-
GCAGTTCTGAAACAGTTTCTTTCTCGAGAAAGAAACT-
GTTTCAGAACTGTTTTT and the control was: SHC004
(MISSION TRC2-pLKO puro TurboGFP shRNA Control
vector): CCGGCGTGATCTTCACCGACAAGATCTCGAGA-
TCTT GTCGGTGAAGATCACGTTTTT. HPV16+ KCs were
seeded 7.56104 cells per well to a 12-wells plate in K-SFM and
were allowed to attach over night. Medium was replaced by
infection medium (K-SFM+30% virus supernatant; MOI=5),
containing either the lentivirus LV079 in IMDM 5% FCS or as
control SHC004. HPV16+ KCs were infected over night after
which infection medium was replaced by K-SFM containing
1000 ng/ml puromycin for 48 hours to select for successfully
infected HPV16+ KCs. Then the medium was replaced by K-
SFM without puromycin and cells were grown for 24 hours. To
stimulate the PRR pathways lentivirus-infected HPV16+ KCs
were given K-SFM containing either no poly(I:C) (two wells) or
25 ug/ml poly(I:C) and were cultured for 21 hours. Then one of
the two non-stimulated wells received 25 ug/ml poly(I:C) and all
cells were cultured for another 3 hours. Cells were harvested and
total RNA was isolated.
Silencer Select siRNA against HPV16 E2 (AACACUACACC-
CAUAGUACAUtt) was designed using siRNA Target Finder
software (Ambion, Invitrogen). Blast search revealed that the
designed E2 siRNA does not match with the known human
transcriptome. E2 and Negative control #2 (NC2) siRNA
(sequence not provided by manufacturer) were purchased from
Ambion. HPV16+ KCs were transfected with 50 nM siRNA E2
or NC2 using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. 48 hours post-transfection cells re-
ceived K-SFM containing no Poly(I:C) or 25 ug/ml Poly(I:C) and
were cultured for 24 hours after which target gene expression was
assayed by qRT-PCR.
Western blot analysis and immunoprecipitation
For Western blotting, polypeptides were resolved by SDS–
polyacrylamide gel electrophoresis (SDS–PAGE) and transferred
to a PVDF membrane (Bio-Rad, Veenendaal, The Netherlands).
Immunodetection was achieved with anti-Flag (1:2000, Sigma-
Aldrich), anti-HA (1:1000, Covance), anti-TRAF3, anti-TRAF6
(both 1:500, Santa Cruz, CA), anti-ubiquitin lysine 48-specific
(1:1000, Millipore, Amsterdam, The Netherlands), anti-poly-
ubiquitin lysine 63 specific (1:1000, Millipore), anti-TBK1
(1:400, Santa Cruz), anti-NEMO (FL-419, Santa Cruz), anti-
UCHL1 (1:1000 Millipore, 1:100 Abcam or 1:1000 Santa Cruz),
anti-USP8 (#8728, Cell Signaling Technology, Danvers, MA,
USA), anti-phospho-p65 (Ser538; 1:1000, #3033 Cell Signaling
Technology) and anti-phospho-IRF3 (Ser396; 1:2000, #4947,
Cell Signaling Technology) or b-actin (1:10,000, Sigma-Aldrich)
antibodies. The proteins were visualized by a chemoluminescence
reagent (Thermo Scientific, Etten-Leur, The Netherlands). X-Ray
films were scanned using a GS-800 calibrated densitometer and
Quantity One software (Bio-Rad, Veenendaal, The Netherlands)
to quantify the intensity of the bands as a measure of the amount
of protein of interest in the blot. The relative amount was
determined by calculating the ratio of each protein over that of the
density measured for the household protein b-Actin.
For immunoprecipitation, cells were collected after 48 h and
then lysed in NP40 buffer supplemented with a complete protease
inhibitor cocktail (Roche, Almere, The Netherlands). After pre-
clearing with protein A/G agarose beads for 1 h at 4uC, whole-cell
lysates were used for immunoprecipitation with either mouse or
rabbit anti-Flag antibodies (Sigma-Aldrich), or rabbit anti-TRAF3
or rabbit anti-TRAF6. One to two mg of the antibody was added
to 1 ml of cell lysate, which was incubated at 4uC for 2–3 h. After
addition of protein A/G agarose beads, the incubation was
continued for 1 h. Immunoprecipitates were extensively washed
with lysis buffer and eluted with SDS loading buffer and boiled for
5 min. For immunoprecipitation under denaturing conditions,
proteins were extracted using regular immunoprecipitation buffer
plus 1% SDS and heated at 95uC for 5 min. The samples were
diluted (10-fold) in regular immunoprecipitation buffer before
immunoprecipitation.
Supporting Information
Figure S1 Cytokine production by poly(I:C)-stimulated
terminally differentiated keratinocytes. IL-8 and MIP3a
expression levels in unstimulated or poly(I:C)-stimulated uninfect-
ed KCs as examined by real-time PCR. KC were either left
undifferentiated (undif) or terminally differentiated (terminal dif)
with methylcellulose containing Ca2+. Gene expression was
normalized using GAPDH.
(EPS)
Figure S2 NEMO degradation depends on the expres-
sion of UCHL1. NEMO degradation is enhanced in HPV16+
KCs but not in non-infected KCs. Monolayer cultures were
treated with different concentrations of cycloheximide (CHX) for
24 hours. Whole cell extracts were analyzed by WB using
antibodies against NEMO and b-actin (control for protein
content).
(EPS)
Figure S3 Restored cytokine production after knock
down of UCHL1 by RNAi oligos. HPV16+ keratinocytes were
transfected with non-targeting RNAi oligos and oligos targeting
UCHL1. Cells were either left unstimulated, or were stimulated
with poly(I:C) for 24 hrs. IL-8,and MIP3a mRNA expression was
analyzed by qRT-PCR. Gene expression was normalized against
GAPDH mRNA levels.
(EPS)
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Figure S4 TRAF3 and NEMO are deubiquitinated by
UCHL1. HEK293T cells were co-transfected with HA-tagged
wild-type ubiquitin (WT-Ub) only, with Flag-TRAF3 and HA-
tagged wild-type ubiquitin (WT-Ub), and with Flag-TRAF3 and
HA-tagged wild-type ubiquitin (WT-Ub) and UCHL1. A similar
experiment was performed in which Flag-TRAF3 was replaced by
Flag-NEMO (top panels). The bottom four panels show a WB
analysis of Flag,Wt-Ub, and UCHL1 of non- immunoprecipitated
lysate and a Ponceau S stained loading control for WB.
(EPS)
Table S1 Enrichment of pathways between HPV-posi-
tive and uninfected keratinocytes as analyzed by Inge-
nuity Pathway Analysis (IPA).
(DOC)
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